#7 - Dyne Therapeutics (NASDAQ:DYN)
The field of stocks under $50 is filled with many biotechnology companies. Taking a position in these companies while they’re still in the clinical trial stage can reap huge gains if they successfully bring a drug to market.
That’s the case with Dyne Therapeutics Inc. (NASDAQ: DYN). The company’s FORCE platform is targeting muscle diseases with the goal of stopping or potentially reversing the progression of diseases such as myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD).
The company’s lead candidates, DYNE-101 and DYNE-251, are in early-stage trials. That puts the company years away from revenue and earnings. However, analysts are bullish on DYN stock with a consensus Buy rating and a $37.43 price target.
Investors looking to take a long position must be patient as short interest is above 16%, which could lead to short-term volatility. But companies like these require a belief in the story. In this case, you won’t be alone.
About Dyne Therapeutics
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Read More - Current Price
- $29.69
- Consensus Rating
- Buy
- Ratings Breakdown
- 9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $51.40 (73.1% Upside)
As of April 2024, there are about 6,000 publicly traded companies on the New York Stock Exchange (NYSE) and the Nasdaq (NASDAQ). And the list of those that trade under $50 is much larger than the seven stocks on this list.
MarketBeat has several tools that make it easy to find stocks under $50. The most direct way is to go to the Market Data drop-down menu and find Low Priced Stocks. There, you'll find “Stocks Under $50." This provides a list of stocks that consistently receive “Buy" and “Strong Buy" ratings from Wall Street's top analysts.
You can also use MarketBeat's free stock screener tool and filter for stocks with a maximum price of $50. The screener also allows you to filter for other attributes, such as market cap or market sector. If dividends are important to you, you can also screen for that.
It's another way that MarketBeat can be a one-stop resource to help make you a more informed investor.
More Investing Slideshows:
